IL6 and acute respiratory distress syndrome: Since one of the principal reasons of developing acute lung injury and ARDS in COVID-19 pneumonia is the overexpression of the immune system, blocking IL-6 would stop the activation of innate immune cells (like neutrophils and macrophages) [6], which eventually leads to the development of CSS and therefore, have a decrease in mortality in critically ill patients [14,15].